A phase I, multicenter, open-label, first-in-human study to evaluate MEDI0680, an anti-programmed cell death-1 antibody, in patients with advanced malignancies

TPS3088 Background: Programmed cell death-1 (PD-1) is an inhibitory regulator or checkpoint of T-cell activation. Recent data from several large phase I studies have shown that targeting the PD-1/p...